STRO
SUTRO BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$11.26
+2.88%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-49.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 22, 2026 | Gerber Hans-Peter · officer: CHIEF SCIENTIFIC OFFICER | M-Exempt | 3,750 | $0.00 |
| Sep 22, 2026 | Gerber Hans-Peter · officer: CHIEF SCIENTIFIC OFFICER | F-InKind | 1,345 | $15 |
| Jun 9, 2026 | MATSUI CONNIE · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Jagpal Sukhi · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | PANEK JAMES P · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Dybbs Michael · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Wigginton Jon Marc · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Lobacki Joseph M · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Petree Daniel H · director | A-Award | 10,000 | $26 |
| Jun 9, 2026 | Hunter Heidi · director | A-Award | 10,000 | $26 |
| Jun 2, 2026 | Chow Gregory K. · officer: CFO | M-Exempt | 2,500 | $0.00 |
| Mar 6, 2026 | Chung Jane · director, officer: Chief Executive Officer | M-Exempt | 788 | $0.00 |
| Mar 6, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | F-InKind | 277 | $21 |
| Mar 6, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | M-Exempt | 675 | $0.00 |
| Mar 6, 2026 | Chung Jane · director, officer: Chief Executive Officer | F-InKind | 282 | $21 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | A-Award | 33,600 | $21 |
| Mar 3, 2026 | Gerber Hans-Peter · officer: CHIEF SCIENTIFIC OFFICER | M-Exempt | 1,125 | $0.00 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | F-InKind | 551 | $20 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | A-Award | 40,000 | $0.00 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | M-Exempt | 688 | $0.00 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | A-Award | 175,000 | $21 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | F-InKind | 970 | $21 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | F-InKind | 2,779 | $21 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | A-Award | 4,200 | $0.00 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | M-Exempt | 2,356 | $0.00 |
| Mar 3, 2026 | Chung Jane · director, officer: Chief Executive Officer | M-Exempt | 2,500 | $0.00 |
| Mar 3, 2026 | Pauling David · officer: Chief Admin. Ofcr. & GC | M-Exempt | 842 | $0.00 |
| Mar 3, 2026 | Chow Gregory K. · officer: CFO | A-Award | 40,000 | $21 |
| Mar 3, 2026 | Gerber Hans-Peter · officer: CHIEF SCIENTIFIC OFFICER | F-InKind | 1,170 | $21 |
| Mar 3, 2026 | Gerber Hans-Peter · officer: CHIEF SCIENTIFIC OFFICER | A-Award | 5,000 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 66Increased 46Reduced 32Sold out 17
| Filer | Action | Shares | Filed |
|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | Increased | 1,304,846 | Aug 14, 2026 |
| BVF INC/IL | Unchanged | 1,251,788 | Aug 14, 2026 |
| BVF INC/IL | New Position | 1,251,788 | May 15, 2026 |
| Affinity Asset Advisors, LLC | Increased | 1,172,487 | Aug 13, 2026 |
| BlackRock, Inc. | Increased | 1,122,655 | Aug 7, 2026 |
| AFFINITY ASSET ADVISORS, LLC | Increased | 1,069,519 | May 14, 2026 |
| Samsara BioCapital, LLC | Unchanged | 1,062,872 | Aug 14, 2026 |
| SAMSARA BIOCAPITAL, LLC | Increased | 1,062,872 | May 15, 2026 |
| Kynam Capital Management, LP | Unchanged | 872,558 | Aug 14, 2026 |
| KYNAM CAPITAL MANAGEMENT, LP | Increased | 872,558 | May 15, 2026 |
| ORBIMED ADVISORS LLC | New Position | 801,144 | May 15, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 743,944 | Aug 14, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 720,442 | May 15, 2026 |
| PERCEPTIVE ADVISORS LLC | New Position | 715,307 | May 29, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | New Position | 715,307 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 22, 2026